RBFOX1与阿尔茨海默氏症发病时的年龄相关
Laura Xicota1,2, Rong Cheng1,3, Stacy L Andersen4
1Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 22, 2026
概括
在RBFOX1中的遗传变异可能会影响早期阿尔茨海默病 (AD) 发病时间. 这一发现表明RBFOX1是延迟痴呆症发病的潜在治疗点.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 早期阿尔茨海默病 (AD) 遗传因素超出已知的基因 (APP,PSEN1/2) 基本上未被确定.
- 识别新的遗传位置对于理解AD机制和发现治疗点至关重要.
- 长寿家庭研究 (LLFS) 提供了一个队列,用于调查早期出现AD的遗传影响.
研究的目的:
- 为了确定与早期阿尔茨海默病发病时的年龄相关的新型遗传变异.
- 探索已识别的遗传因素在疾病机制和认知表型中的作用.
- 为早期发病的AD提名潜在的治疗点.
主要方法:
- 对六个早期发病的AD家族进行了全基因组链接分析和单核酸多态 (SNP) 关联研究.
- 验证分析涉及9个独立队列,以确认遗传关联.
- 进行了血液和大脑转录组分析,以调查基因表达模式.
主要成果:
- 确定了三个重要的联系区域,其中RBFOX1显示出强烈的关联 (LOD = 4.41).
- RBFOX1变种与发病时的年龄和早期发病的AD的认知表型有显著联系.
- 血液中的RBFOX1过度表达与早期发病的阿尔茨海默病相关,在验证队列中得到证实.
结论:
- 基因RBFOX1被认为是影响早期阿尔茨海默病发病年龄的潜在因素.
- RBFOX1代表了旨在延迟或预防痴呆症的干预措施的有希望的治疗标.
- 对RBFOX1作用的进一步研究可能会揭示阿尔茨海默病治疗的新途径.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.8K
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
8.8K
相关概念视频
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
